Nine different inhibitors (9KiP) were selected to maximize the coverage of kinases relevant for breast cancer: Palbociclib (CDK4/6 inhibitor), Crizotinib (c-MET and AXL inhibitor), CZC-8004 (non-specific tyrosine kinase inhibitor), Axitinib (VEGFR and PDGFR inhibitor), GSK690693 (AKT inhibitor), AZD4547 (FGFR and VEGF inhibitor), Afatinib (EGFR and ERBB2 inhibitor), Abemaciclib (CDK4/6 inhibitor), and FRAX597 (PAK inhibitor) (Fig. 1A). This evidence concerns the gene PDGFRB and breast carcinoma.